Navigation Links
Lung cancer cells activate inflammation to induce metastasis
Date:12/31/2008

A research team from the University of California, San Diego School of Medicine has identified a protein produced by cancerous lung epithelial cells that enhances metastasis by stimulating the activity of inflammatory cells. Their findings, to be published in the January 1 issue of the journal Nature, explain how advanced cancer cells usurp components of the host innate immune system to generate an inflammatory microenvironment hospitable for the metastatic spread of lung cancer. The discovery could lead to a therapy to limit metastasis of this most common lethal form of cancer.

The scientists headed by Michael Karin, Ph.D., UC San Diego Distinguished Professor of Pharmacology and Pathology, who has been investigating the effects of inflammation on cancer development and progression used a straightforward biochemical approach to identify proteins produced by metastatic cancer cells that are responsible for generation of an inflammatory microenvironment that supports the growth of metastases. Focusing on macrophages, white blood cells that are key players in the immune response to foreign invaders as well as in cancer growth and progression, they screened for factors produced by metastatic cancer cells in mice that could stimulate the activity of this inflammatory cell type.

Among the mouse cell lines screened, a highly metastatic cell line called Lewis lung carcinoma (LLC) showed particularly potent activation of macrophages. Furthermore, macrophage activation was mediated by a secreted protein. Biochemical purification of proteins secreted by LLC cells resulted in identification of an extracellular matrix protein called versican as the major macrophage activator and metastasis enhancing factor. Versican is also found in very low amounts in normal human lung epithelial cells, but is upregulated in human lung cancer, where a very large amount of this protein is found, especially in aggressive tumors.

The scientists found that versican strongly enhances LLC metastatic growth by activating receptors that lead to production of cytokines signaling proteins that regulate the immune system. One of these receptors, TLR2, and a cytokine, TNFα, were found to be required for LLC metastasis. However, the normal function of TLR2 and TNF is in host defense-innate immunity to microbial infections. According to Karin, these findings are relevant, not just to the mouse model, but also to human lung cancer the most common cause of cancer-related deaths worldwide. The major cause of lung cancer is tobacco smoking.

"By usurping these elements of the host immune system, versican helps generate an inflammatory environment that spurs the growth and spread of metastatic cancer," said Karin. "If we can find a way to block the production of versican or its binding to TLR2, therapeutic intervention could be used to limit metastasis of lung cancer."


'/>"/>

Contact: Debra Kain
ddkain@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Related medicine news :

1. Why prostate cancer patients fail hormone deprivation therapy
2. Few DNA repair genes maintain association with cancer in field synopsis
3. High Insulin May Boost Odds of Breast Cancer
4. Vitamins Fail to Prevent Cancer: Study
5. Errors involving medications common in outpatient cancer treatment
6. Young blood fights cancer
7. Food Phosphates Might Spur Lung Cancer
8. Minimizing obesitys impact on ovarian cancer survival
9. RCOG.com and ProstRcision.com Increase Online Presence for Cancer Information
10. Lung Cancer: Still the Biggest Cancer Killer, by Far
11. Cancer drug effectively treats transplant rejections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... Life is known for throwing curves. ... and older, who gather once a year to play softball to raise money through ... game, the more than 50 players who competed in this year’s softball tournament share ...
(Date:2/11/2016)... ... ... Colorado spine surgeon, Donald Corenman, MD, DC has been selected by ... . The list consists of spine surgeons across the country nominated by their peers ... importance of clinical excellence; he has been awarded the Patient’s Choice Award, Compassionate Doctor ...
(Date:2/11/2016)... ... 2016 , ... Talix today announced that Clive Fields, MD, ... at the 2016 HIMSS Annual Conference & Exhibition, taking place February 29 – ... Coding for Care: Using Data Analytics for Risk Adjustment ,” Dr. Fields will ...
(Date:2/11/2016)... AR (PRWEB) , ... February 11, 2016 , ... Dickinson ... their community by announcing a new fundraiser in support of a local boy named ... hopes the campaign will bring awareness to, and rally support for, all local families ...
(Date:2/11/2016)... ... February 11, 2016 , ... Pixel Film Studios brings ... with customizable backdrops in the Christmas edition of the ProDrop series. Pick and choose ... audiences and invoke the spirit of Christmas using ProDrop's wintry generators. ProDrop Christmas is ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Breast Cancer Therapeutics in Asia-Pacific Markets ... (APAC) breast cancer market will experience considerable expansion ... at a Compound Annual Growth Rate (CAGR) of 8.5%. ... - states that the Asia-Pacific ... billion in 2014 to $3.4 billion by 2021, at a ...
(Date:2/11/2016)... , Feb. 11, 2016 PLAD, Inc. ... out 2016 with sales exceeding company targets, are adding ... received their trademark from the United States Patent and ... Clark , Chief Executive Officer of PLAD, Inc.  In ... Pennsylvania with two new customers, ...
(Date:2/11/2016)... 11, 2016  M3 Biotechnology Inc., spurred by a major "team investment" by Bruce Montgomery ... completed an oversubscribed Series A-Round, according to CEO Leen Kawas , PhD. ... ... ... Kawas said ...
Breaking Medicine Technology: